Gene therapy · Gene replacement · developed by Krystal Biotech
KB111 is a replication-defective, non-integrating herpes simplex virus type 1-based vector that encodes full-length human ATP2C1 protein, formulated as a gel for topical application. It is studied in Hailey-Hailey disease, a benign familial skin disease, and other skin lesions.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07717346 | Early Phase 1 | Hailey Hailey Disease | Recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hailey Hailey DiseaseLesion SkinSkin Diseases
Updated Oct 25, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →